Hutchmed (China) Limited Blocklisting Six Monthly Return

RNS Number : 4425R

Hutchmed (China) Limited

30 December 2024

 

Blocklisting Six Monthly Return

 

Hong Kong, Shanghai & Florham Park, NJ - Monday, December 30, 2024: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

 

1.	Name of applicant:		HUTCHMED (China) Limited
2.	Name of scheme:		Share Option Scheme conditionally adopted by HUTCHMED in 2015 ("2015 HUTCHMED Share Option Scheme")
3.	Period of return:		From June 29, 2024 to December 28, 2024
4.	Balance under scheme from previous return:		2015 HUTCHMED Share Option Scheme: 46,743,768 ordinary shares of US$0.1 each
5.	The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		2015 HUTCHMED Share Option Scheme: Nil
6.	Number of securities issued/allotted under scheme during period:		2015 HUTCHMED Share Option Scheme: 241,375
7.	Balance under scheme not yet issued/allotted at end of the period:		2015 HUTCHMED Share Option Scheme: 46,502,393 ordinary shares of US$0.1 each
8.	Number and class of securities originally listed and the date of admission:		25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019)
9.	Total number of securities in issue at the end of the period:		871,601,095 ordinary shares of US$0.1 each
Name of contact:			Weiguo Su
Address of contact:			Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong
Telephone number of contact:			[phone]

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/​immunology. Since inception it has focused on bringing cancer drug candidates from in‑house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit www.hutch-med.com or follow us on LinkedIn.

CONTACTS

 

Investor Enquiries	[phone] / [e-mail]
Media Enquiries
Ben Atwell / Alex Shaw, FTI Consulting	[phone] / [phone] (Mobile) / [phone] (Mobile) / [e-mail]
Zhou Yi, Brunswick	[phone] (Mobile) / [e-mail]
Nominated Advisor
Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Liberum	[phone]

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BLREANAXAANLFEA